Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortization of GoodwillAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Harvard Bioscience (HBIO) Depreciation & Amortization (CF) (2016 - 2025)

Historic Depreciation & Amortization (CF) for Harvard Bioscience (HBIO) over the last 17 years, with Q3 2025 value amounting to $425000.0.

  • Harvard Bioscience's Depreciation & Amortization (CF) fell 274.6% to $425000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $1.7 million, marking a year-over-year increase of 362.02%. This contributed to the annual value of $1.7 million for FY2024, which is 1513.33% up from last year.
  • According to the latest figures from Q3 2025, Harvard Bioscience's Depreciation & Amortization (CF) is $425000.0, which was down 274.6% from $411000.0 recorded in Q2 2025.
  • Harvard Bioscience's 5-year Depreciation & Amortization (CF) high stood at $470000.0 for Q4 2021, and its period low was $331000.0 during Q4 2022.
  • Its 5-year average for Depreciation & Amortization (CF) is $407789.5, with a median of $418000.0 in 2023.
  • Its Depreciation & Amortization (CF) has fluctuated over the past 5 years, first plummeted by 2957.45% in 2022, then skyrocketed by 2861.45% in 2024.
  • Harvard Bioscience's Depreciation & Amortization (CF) (Quarter) stood at $470000.0 in 2021, then dropped by 29.57% to $331000.0 in 2022, then grew by 25.98% to $417000.0 in 2023, then increased by 10.07% to $459000.0 in 2024, then decreased by 7.41% to $425000.0 in 2025.
  • Its last three reported values are $425000.0 in Q3 2025, $411000.0 for Q2 2025, and $451000.0 during Q1 2025.